{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-115980","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.057219+00:00","generated_at":"2026-05-15T09:36:36.610970+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead","bullets":["Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).","Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.","Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.","Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.","Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-115980","json":"https://secwatch.observer/filing/0001193125-26-115980.json","markdown":"https://secwatch.observer/filing/0001193125-26-115980.md","text":"https://secwatch.observer/filing/0001193125-26-115980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/0001193125-26-115980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/asmb-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:36:36.610970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ea34b635e3de408a2e491719ac3c09340b55430","claim":"ASSEMBLY BIOSCIENCES, INC. reported the year ended December 31, 2025 results: revenue $72.3 million, net income Net loss attributable to common stockholders was $6.1 million, EPS $0.55 per basic and diluted share.","evidence_excerpt":"Year-End 2025 Financial Results • Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of the year ended December 31, 2024. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, compared to $28.5 million in 2024. The increase reflects the increase in collaboration funding. • Research and development expenses were $64.8 million for the year ended December 31, 2025, compared to $55.9 million in 2024. The increase is largely driven by an increase in spending on the HPI program, as both ABI-1179 and ABI-5366 saw significant enrollment in their respective Phase 1b clinical studies during the current year. • General and administrative expenses were $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024. The increase was primar","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/0001193125-26-115980-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$72.3 million"},{"label":"Net income","value":"Net loss attributable to common stockholders was $6.1 million"},{"label":"EPS","value":"$0.55 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}